The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells

View/ Open
Author
Gomez-Casal, Roberto
Bhattacharya, Chitralekha
Epperly, Michael W.
Basse, Per H.
Wang, Hong
Proia, David A.
Greenberger, Joel S.
Socinski, Mark A.
Levina, Vera
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.3390/cancers7020814Metadata
Show full item recordCitation
Gomez-Casal, Roberto, Chitralekha Bhattacharya, Michael W. Epperly, Per H. Basse, Hong Wang, Xinhui Wang, David A. Proia, Joel S. Greenberger, Mark A. Socinski, and Vera Levina. 2015. “The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.” Cancers 7 (2): 876-907. doi:10.3390/cancers7020814. http://dx.doi.org/10.3390/cancers7020814.Abstract
The molecular chaperone HSP90 is involved in stabilization and function of multiple client proteins, many of which represent important oncogenic drivers in NSCLC. Utilization of HSP90 inhibitors as radiosensitizing agents is a promising approach. The antitumor activity of ganetespib, HSP90 inhibitor, was evaluated in human lung adenocarcinoma (AC) cells for its ability to potentiate the effects of IR treatment in both in vitro and in vivo. The cytotoxic effects of ganetespib included; G2/M cell cycle arrest, inhibition of DNA repair, apoptosis induction, and promotion of senescence. All of these antitumor effects were both concentration- and time-dependent. Both pretreatment and post-radiation treatment with ganetespib at low nanomolar concentrations induced radiosensitization in lung AC cells in vitro. Ganetespib may impart radiosensitization through multiple mechanisms: such as down regulation of the PI3K/Akt pathway; diminished DNA repair capacity and promotion of cellular senescence. In vivo, ganetespib reduced growth of T2821 tumor xenografts in mice and sensitized tumors to IR. Tumor irradiation led to dramatic upregulation of β-catenin expression in tumor tissues, an effect that was mitigated in T2821 xenografts when ganetespib was combined with IR treatments. These data highlight the promise of combining ganetespib with IR therapies in the treatment of AC lung tumors.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491689/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:17820921
Collections
- HMS Scholarly Articles [17723]
Contact administrator regarding this item (to report mistakes or request changes)